173 related articles for article (PubMed ID: 20550533)
41. Reduced 11beta-hydroxysteroid dehydrogenase activity in patients with the nephrotic syndrome.
Vogt B; Dick B; N'Gankam V; Frey FJ; Frey BM
J Clin Endocrinol Metab; 1999 Feb; 84(2):811-4. PubMed ID: 10022459
[TBL] [Abstract][Full Text] [Related]
42. Exaggerated adrenarche and altered cortisol metabolism in Type 1 diabetic children.
Remer T; Maser-Gluth C; Boye KR; Hartmann MF; Heinze E; Wudy SA
Steroids; 2006 Jul; 71(7):591-8. PubMed ID: 16616286
[TBL] [Abstract][Full Text] [Related]
43. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
Mahmud A; Mahgoub M; Hall M; Feely J
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
[TBL] [Abstract][Full Text] [Related]
44. Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans.
Hosoya K; Minakuchi H; Wakino S; Fujimura K; Hasegawa K; Komatsu M; Yoshifuji A; Futatsugi K; Shinozuka K; Washida N; Kanda T; Tokuyama H; Hayashi K; Itoh H
Kidney Int; 2015 Apr; 87(4):749-60. PubMed ID: 25337775
[TBL] [Abstract][Full Text] [Related]
45. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
[TBL] [Abstract][Full Text] [Related]
46. Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients.
Henger A; Tutt P; Riesen WF; Hulter HN; Krapf R
J Lab Clin Med; 2000 Nov; 136(5):379-89. PubMed ID: 11079465
[TBL] [Abstract][Full Text] [Related]
47. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
[TBL] [Abstract][Full Text] [Related]
48. Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: a mechanism for increased stress vulnerability?
Steen NE; Methlie P; Lorentzen S; Hope S; Barrett EA; Larsson S; Mork E; Almås B; Løvås K; Agartz I; Melle I; Berg JP; Andreassen OA
J Clin Psychiatry; 2011 Nov; 72(11):1515-21. PubMed ID: 21367348
[TBL] [Abstract][Full Text] [Related]
49. Familial pattern of corticosteroids and their metabolism in adult human subjects--the Scottish Adult Twin Study.
Inglis GC; Ingram MC; Holloway CD; Swan L; Birnie D; Hillis WS; Davies E; Fraser R; Connell JM
J Clin Endocrinol Metab; 1999 Nov; 84(11):4132-7. PubMed ID: 10566661
[TBL] [Abstract][Full Text] [Related]
50. Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.
Sato A; Fukuda S
Hypertens Res; 2013 Oct; 36(10):879-84. PubMed ID: 23864056
[TBL] [Abstract][Full Text] [Related]
51. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
Barr CS; Lang CC; Hanson J; Arnott M; Kennedy N; Struthers AD
Am J Cardiol; 1995 Dec; 76(17):1259-65. PubMed ID: 7503007
[TBL] [Abstract][Full Text] [Related]
52. 11beta-hydroxysteroid dehydrogenase 2 activity is elevated in severe obesity and negatively associated with insulin sensitivity.
Müssig K; Remer T; Haupt A; Gallwitz B; Fritsche A; Häring HU; Maser-Gluth C
Obesity (Silver Spring); 2008 Jun; 16(6):1256-60. PubMed ID: 18421276
[TBL] [Abstract][Full Text] [Related]
53. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
Williams B; MacDonald TM; Morant SV; Webb DJ; Sever P; McInnes GT; Ford I; Cruickshank JK; Caulfield MJ; Padmanabhan S; Mackenzie IS; Salsbury J; Brown MJ;
Lancet Diabetes Endocrinol; 2018 Jun; 6(6):464-475. PubMed ID: 29655877
[TBL] [Abstract][Full Text] [Related]
54. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
Bianchi S; Bigazzi R; Campese VM
Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956
[TBL] [Abstract][Full Text] [Related]
55. 11beta-hydroxysteroid dehydrogenase activity in proteinuric patients and the effect of angiotensin-II receptor blockade.
Kerstens MN; Buter H; Navis GJ; Dullaart RP
Eur J Clin Invest; 2002 Jul; 32(7):513-8. PubMed ID: 12153552
[TBL] [Abstract][Full Text] [Related]
56. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure.
Tsutamoto T; Wada A; Maeda K; Mabuchi N; Hayashi M; Tsutsui T; Ohnishi M; Sawaki M; Fujii M; Matsumoto T; Horie H; Sugimoto Y; Kinoshita M
J Am Coll Cardiol; 2000 Sep; 36(3):838-44. PubMed ID: 10987608
[TBL] [Abstract][Full Text] [Related]
57. Urinary free cortisol is not a biochemical marker of hypertension.
Krall P; Carvajal C; Ortiz E; Muñoz C; Garrido JL; Mosso L; Fardella C
Am J Hypertens; 2007 Apr; 20(4):459-65. PubMed ID: 17386356
[TBL] [Abstract][Full Text] [Related]
58. Urinary cortisol to cortisone metabolites in hypertensive obese children.
Csábi GY; Juricskay S; Molnár D
J Endocrinol Invest; 2000; 23(7):435-9. PubMed ID: 11005267
[TBL] [Abstract][Full Text] [Related]
59. Altered glucocorticoid metabolism in girls with central obesity.
Kim SH; Kim SE; Choi MH; Park MJ
Mol Cell Endocrinol; 2021 May; 527():111225. PubMed ID: 33640459
[TBL] [Abstract][Full Text] [Related]
60. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man.
Palermo M; Shackleton CH; Mantero F; Stewart PM
Clin Endocrinol (Oxf); 1996 Nov; 45(5):605-11. PubMed ID: 8977758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
